PMC:7195088 / 65816-67201
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1895 | 553-561 | Species | denotes | patients | Tax:9606 |
1900 | 567-575 | Disease | denotes | COVID-19 | MESH:C000657245 |
1922 | 112-122 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1923 | 189-199 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1924 | 221-229 | Species | denotes | SARS-CoV | Tax:694009 |
1925 | 400-410 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1927 | 236-245 | Species | denotes | influenza | Tax:11520 |
1928 | 471-478 | Chemical | denotes | LPV/RTV | MESH:C558899 |
1929 | 542-549 | Chemical | denotes | LPV/RTV | MESH:C558899 |
1930 | 867-874 | Chemical | denotes | LPV/RTV | MESH:C558899 |
1931 | 1068-1075 | Chemical | denotes | LPV/RTV | MESH:C558899 |
1932 | 1270-1277 | Chemical | denotes | LPV/RTV | MESH:C558899 |
1933 | 285-294 | Disease | denotes | mortality | MESH:D003643 |
1935 | 1315-1323 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T376 | 112-120 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T377 | 189-197 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T378 | 221-229 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T379 | 236-245 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T380 | 400-408 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T381 | 567-575 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T382 | 1315-1323 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T365 | 93-100 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T366 | 253-254 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T367 | 691-693 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T368 | 784-786 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T11348 | 36-45 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T12438 | 318-327 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T94861 | 726-730 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T14598 | 1090-1100 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
T18588 | 1291-1301 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T467 | 0-200 | Sentence | denotes | Most clinical data on the timing of antiviral therapy initiation are derived from studies on viruses other than SARS-CoV-2, and it remains unclear whether these data can be extrapolated to SARS-CoV-2. |
T468 | 201-384 | Sentence | denotes | Previous studies in SARS-CoV-1 and influenza showed a possible favourable impact on mortality of early initiation of antiviral treatment after symptoms onset [[79], [80], [81], [82]]. |
T469 | 385-788 | Sentence | denotes | With regard to SARS-CoV-2, although the results of the previously cited RCT comparing LPV/RTV versus standard of care eventually does not support the use of LPV/RTV in patients with COVID-19, it is also of note that the median time between symptom onset and randomization was 13 days (interquartile range, 11–16 days), so in most cases, the drug was initiated late during the course of the disease [22]. |
T470 | 789-917 | Sentence | denotes | Consequently, we cannot exclude the possibility that an earlier initiation of LPV/RTV may be associated with improved prognosis. |
T471 | 918-1137 | Sentence | denotes | In this regard, we think the results of this RCT may be hypothesis generating and may help guide the design of further RCT evaluating the efficacy of LPV/RTV (and/or other antivirals) in an earlier phase of the disease. |
T472 | 1138-1385 | Sentence | denotes | However, until such RCT will be available, we think the currently available clinical evidence is insufficient to support the use of LPV/RTV and/or other antivirals for treating COVID-19 outside the framework of RCT or compassionate-use programmes. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32360444-14660806-22369819 | 361-363 | 14660806 | denotes | 79 |
32360444-30304487-22369820 | 367-369 | 30304487 | denotes | 80 |
32360444-22843781-22369821 | 373-375 | 22843781 | denotes | 81 |
32360444-24815805-22369822 | 379-381 | 24815805 | denotes | 82 |
32360444-32187464-22369823 | 784-786 | 32187464 | denotes | 22 |